

## Terpenoids of *Syzygium formosanum*

Chung-Werng Chang,<sup>†</sup> Tien-Shung Wu,<sup>‡</sup> Yih-Shou Hsieh,<sup>§</sup> Sheng-Chu Kuo,<sup>†</sup> and Pei-Dawn Lee Chao<sup>\*,†</sup>

Institute of Pharmaceutical Chemistry, China Medical College, Taichung, Taiwan, Republic of China

Received July 17, 1998


A new natural product, 4-epifriedelin (**1**), and 12 known terpenoids have been isolated from the leaves of *Syzygium formosanum*. The known compounds include caryophyllene oxide, friedelin, canophyllal, glutinol,  $\alpha$ -terpineol, phytol, betulinic acid, uvaol, lupeol, betulin, ursolic acid, and oleanolic acid. All of these compounds are reported for the first time from *S. formosanum*.

*Syzygium formosanum* (Hay.) Mori (Myrtaceae) is endemic to Taiwan. In the course of our continuing search for anti-HIV agents from natural products, a 70% acetone extract of the leaves demonstrated promising inhibition of Moloney murine leukemia virus (Mo-MuLV) reverse transcriptase. The acetone extract was partitioned between H<sub>2</sub>O and CH<sub>2</sub>Cl<sub>2</sub>, and the CH<sub>2</sub>Cl<sub>2</sub> fraction still showed inhibitory effects on Mo-MuLV reverse transcriptase. This study reports the isolation of 13 terpenoids from this fraction, all of them reported for the first time from this plant, of which **1** is a new natural product.

Compound **1** was obtained as colorless needles. Its IR spectrum exhibited a band for carbonyl (1717 cm<sup>-1</sup>). The <sup>13</sup>C NMR spectrum of compound **1** revealed chemical shifts of carbons on C, D, and E rings very similar to those of friedelin, but two methyl carbons were found further downfield than friedelin ( $\delta$  13.5, 23.1 vs  $\delta$  6.8, 14.6). HMQC of **1** revealed that the proton attached to the carbon at  $\delta$  13.5 was a doublet ( $J = 7.3$  Hz), indicating this carbon was assignable to C-23. Based on the above data, compound **1** appeared to be the C-4 epimer of friedelin. Upon standing in CDCl<sub>3</sub> for one month after NMR measurement, compound **1** had its <sup>13</sup>C NMR spectrum recorded again, it indicated the coexistence of friedelin<sup>1</sup> with compound **1** (ratio ca. 1:1). The mixture was then separated again by HPLC to afford compound **1** and friedelin. Therefore, the structure of **1** was determined to be 4-epifriedelin, a compound not reported previously as a natural product. The structure of **1** was further confirmed by <sup>1</sup>H–<sup>1</sup>H COSY, HMBC, and NOESY techniques. The epimerization of **1** at C-4 in solvent could be accounted for by keto–enol tautomerism of the ketone group at C-3, and the equilibrium favored the more stable configuration of friedelin. 4-Epi-friedelin had been previously reported as a product obtained by photoepimerization of friedelin.<sup>2</sup>

Canophyllal (**2**) was obtained as a yellow powder. It showed 30 carbons, including two carbonyls ( $\delta$  213.4 and 209.1) in the <sup>13</sup>C NMR spectrum and an aldehyde group in <sup>1</sup>H NMR spectrum ( $\delta$  9.48, s, 1H). Upon standing in CDCl<sub>3</sub> for four months, compound **2** was subjected to <sup>13</sup>C NMR again, and it was found to have transformed into a different compound that showed only 29 carbons, including one carbonyl at  $\delta$  213.4. HMQC and HMBC analyses revealed that **3** was of the friedelane type. By comparison with the <sup>13</sup>C NMR spectrum of friedelin, **3** had one less

methyl, and one carbon at  $\delta$  82.7 was shifted downfield from  $\delta$  30.0 in comparison to friedelin. The IR spectrum of **3** showed hydroxyl absorption at 3481 cm<sup>-1</sup>. EIMS exhibited a significant peak at 426 ( $M^+ - H_2O$ ). Based on the above data, **3** was determined as maytensifolin A. Comparison of the <sup>1</sup>H NMR, <sup>13</sup>C NMR, and EIMS with those of maytensifolin A in the literature confirmed this assignment.<sup>3–5</sup> As to the structure of **2**, its <sup>1</sup>H NMR and MS spectral data were identical with those reported for canophyllal.<sup>3</sup> The spontaneous transformation of canophyllal to maytensifolin A has not been reported previously, and the mechanism remains to be elucidated.



Based on the <sup>1</sup>H NMR, <sup>13</sup>C NMR, and MS data, together with their physical constants, the other isolates were characterized as caryophyllene oxide,<sup>6</sup> friedelin,<sup>1</sup> glutinol,<sup>1</sup>  $\alpha$ -terpineol,<sup>7</sup> phytol,<sup>8</sup> betulinic acid,<sup>5,9,10</sup> uvaol,<sup>5,11</sup> lupeol,<sup>5,12</sup> betulin,<sup>5,9,10</sup> ursolic acid,<sup>13</sup> and oleanolic acid.<sup>5,13,14</sup>

Bioactivity tests of the isolates against Mo-MuLV reverse transcriptase indicated that betulinic acid which has previously been reported to show an EC<sub>50</sub> of 1.4  $\mu$ M,<sup>15</sup> was a promising inhibitor of human immunodeficiency virus (HIV).

<sup>†</sup> China Medical College.

<sup>‡</sup> Cheng Kung University.

<sup>§</sup> Chung-Shan Medical and Dental College.

\* To whom correspondence should be addressed. Fax: 886 4 2032146. E-mail: pdlee@cmce.cmc.edu.tw.

## Experimental Section

**General Experimental Procedures.** The preparative HPLC apparatus was equipped with a Shimadzu LC-10S pump and a Waters 410 differential refractometer. LiChrospher Si 60 column (10  $\mu$ m, 25 cm  $\times$  1 cm) was used for separations. Melting points were measured on a Yanaco MP-500 and are uncorrected. UV spectra were obtained on a Shimadzu UV-160A, whereas IR spectra were recorded on a Nicolet Impact 400 FT-IR. EIMS were obtained on a Hewlett-Packard 5995 GC-MS system by direct probe (70 eV). NMR spectra were recorded on Bruker ARX-200, ARX-300 or AMX-400 FT-NMR spectrometers. Optical activities were measured on a JASCO DIP-1000 polarimeter.

**Plant Material.** The leaves of *Syzygium formosanum* (4 kg) were collected in Taipei in September 1994, and identified by Dr. Chung-Chuan Chen of the Institute of Chinese Pharmaceutical Sciences, China Medical College.

**Extraction and Isolation.** The air-dried leaves were blended with 70% Me<sub>2</sub>CO in a juicer. After filtration, Me<sub>2</sub>CO was removed by concentration under reduced pressure. The residue was suspended in H<sub>2</sub>O and partitioned six times with CH<sub>2</sub>Cl<sub>2</sub> to afford an aqueous fraction (700 g) and a CH<sub>2</sub>Cl<sub>2</sub> fraction (105 g).

The CH<sub>2</sub>Cl<sub>2</sub> fraction was chromatographed on a Si gel column and eluted with increasing amounts of EtOAc in *n*-hexane. Further separation was carried out by using Si gel HPLC, which employed isocratic elution with various percentages of EtOAc in *n*-hexane as mobile phases. The chromatographed fraction yielded caryophyllene oxide (15 mg), friedelin (600 mg), 4-epifriedelin (1, 165 mg), canophyllal (2, 10 mg), glutinol (35 mg),  $\alpha$ -terpineol (15 mg), phytol (20 mg), betulinic acid (35 mg), uvaol (25 mg), lupeol (30 mg), betulin (90 mg), ursolic acid (20 mg), and oleanolic acid (15 mg).

**Reverse Transcriptase Assay.** The aforementioned isolates were subjected to an *in vitro* reverse transcriptase assay. Both ( $\gamma$ A)<sub>n</sub>-(dT)<sub>15</sub> and unlabeled TTP were obtained from Boehringer Mannheim GmbH, Penzberg, Germany. <sup>3</sup>H-TTP was purchased from Amersham Co. Reverse transcriptase from Moloney murine leukemia virus (Mo-MuLV) is the product of Bethesda Research Laboratories Life Technologies, Inc., Gaithersburg, MD. The assay reaction mixture (30  $\mu$ L) contained 50 mM Tris-HCl buffer, pH 8.3; 75 mM KCl; 10 mM dithiothreitol; 3 mM MgCl<sub>2</sub>; 0.5  $\mu$ g of ( $\gamma$ A)<sub>n</sub>-(dT)<sub>15</sub>; 0.5  $\mu$ Ci [<sup>3</sup>H]-dTTP, and 5 units of Mo-MuLV reverse transcriptase preparation.<sup>16</sup> After incubation at 37 °C for 30 min, 5  $\mu$ L of 0.4 M EDTA was added to terminate the reaction. The reaction mixture (15  $\mu$ L, in triplicate) was spotted on Whatman DEAE cellulose paper and washed three times each with 5% Na<sub>2</sub>HPO<sub>4</sub>, H<sub>2</sub>O, and EtOH. The radioactivity of the sample was

measured using a Packard 2200 CA, Tri-carb Liquid Scintillation Counter.

**4-Epifriedelin (1):** colorless needles (*n*-hexane-EtOAc); mp 242–245 °C, [ $\alpha$ ]<sub>D</sub> +2.7° (*c* 0.19, CHCl<sub>3</sub>), IR  $\nu_{\max}$  (KBr) cm<sup>-1</sup> 2944, 2863, 1717, 1460, 1381, 1206, 1193, 1058, 978, 953; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  0.80 (3H, s, H-25), 0.85 (1H, m, H-22a), 0.86 (3H, s, H-24), 0.88 (3H, s, H-29), 0.93 (3H, s, H-30), 0.94 (3H, s, H-26), 0.98 (3H, s, H-27), 1.05 (3H, d, *J* = 7.3 Hz, H-23), 1.11 (3H, s, H-28), 1.14 (1H, m, H-6a), 1.16 (2H, m, H-19), 1.23 (1H, m, H-15a), 1.27 (1H, m, H-8), 1.29 (1H, m, H-12), 1.31 (1H, m, H-11a), 1.36 (1H, m, H-11b), 1.44 (1H, m, H-22b), 1.45 (1H, m, H-15b), 1.47 (1H, m, H-18), 1.54 (2H, m, H-1a and H-10), 1.55 (1H, m, H-6b), 1.77 (1H, m, H-1b), 1.84 (1H, m, H-4), 2.24 (1H, m, H-2a), 2.44 (1H, m, H-2b); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) C-1 21.7, C-2 37.1, C-3 216.6, C-4 58.7, C-5 39.9, C-6 37.4, C-7 17.7, C-8 53.5, C-9 37.0, C-10 49.4, C-11 35.7, C-12 30.5, C-13 39.7, C-14 38.3, C-15 32.4, C-16 36.0, C-17 30.0, C-18 42.7, C-19 35.3, C-20 28.1, C-21 32.7, C-22 39.2, C-23 13.5, C-24 23.1, C-25 18.0, C-26 20.4, C-27 18.7, C-28 32.1, C-29 35.0, C-30 31.7; EIMS (*m/z*, %) 426 [M<sup>+</sup>] (8), 341 (3), 302 (7), 273 (12), 246 (12), 205 (17), 179 (19), 163 (31), 137 (26), 125 (44), 123 (53), 109 (68), 95 (100), 81 (71), 69 (91), 55 (72).

## References and Notes

- (1) Akihisa, T.; Yamamoto, K.; Tamura, T.; Kimura, Y.; Iida, T.; Nambara, T.; Chang, C. F. *Chem. Pharm. Bull.* **1992**, *40*, 789–791.
- (2) Aoyaki, R.; Yamada, S.; Tsuyuki, T.; Takahashi, T. *Bull. Chem. Soc. Jpn.* **1973**, *46*, 959–963.
- (3) Nozaki, H.; Suzuki, H.; Hirayama, T.; Kasai, R.; Wu, R. Y.; Lee, K. H. *Phytochemistry* **1986**, *25*, 479–485.
- (4) Patra, A.; Chaudhuri, S. K. *Magn. Reson. Chem.* **1987**, *25*, 95–100.
- (5) Mahato, S. B.; Kundu, A. P. *Phytochemistry* **1994**, *37*, 1517–1575.
- (6) Sashida, Y.; Itokawa, H.; Akita, Y.; Fujita, M. *Yakugaku Zasshi* **1976**, *96*, 218–222.
- (7) Harada, R.; Iwasaki, M. *Phytochemistry* **1982**, *21*, 2009–2011.
- (8) Suga, T.; Aoki, T. *Phytochemistry* **1974**, *13*, 1623–1624.
- (9) Salimuzzaman, S.; Farrukh, H.; Sabira, B.; Bina, S. S. *J. Nat. Prod.* **1988**, *51*, 229–233.
- (10) Sholichin, M.; Yamasaki, K.; Kasai, R.; Tanaka, O. *Chem. Pharm. Bull.* **1980**, *28*, 1006–1008.
- (11) Salimuzzaman, S.; Farrukh, H.; Sabira, B.; Bina, S. S. *J. Nat. Prod.* **1986**, *49*, 1086–1090.
- (12) William, F. R.; Stewart, M.; Janusz, P. *Tetrahedron* **1986**, *42*, 3419–3428.
- (13) Tsutomu, F.; Yutaka, O.; Chisato, H. *Phytochemistry* **1987**, *26*, 715–719.
- (14) Maillard, M.; Adewunmi, C. O.; Hostettmann, K. A. *Phytochemistry* **1992**, *31*, 1321–1323.
- (15) Fujioka, T.; Kashiwada, Y.; Kilkuskie, R. E.; Cosentino, L. M.; Ballas, L. M.; Jiang, J. B.; Janzen, W. P.; Chen, I. S.; Lee, K. H. *J. Nat. Prod.* **1994**, *57*, 243–247.
- (16) Chu, S. C.; Hsieh, Y. S.; Lin, J. Y. *J. Nat. Prod.* **1992**, *55*, 179–183.

NP980313W